Trial Profile
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Tasquinimod (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Active Biotech Research
- 03 Jun 2013 Retrospective follow-up data was presented at the 2013 ASCO Annual Meeting, according to an Active Biotech media release.
- 16 May 2013 Data will be presented at the 2013 ASCO Annual Meeting, according to an Active Biotech media release.
- 01 Oct 2012 Results presented at the European Society for Medical Oncology meeting, according to an Active Biotech media release.